Recent Updates
Recently added Catalysts
PCRX Positive Sentiment

Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November

Key Takeaway: Pacira BioSciences, Inc. (NASDAQ: PCRX) will take part in two notable healthcare conferences in November. The Jefferies London Healthcare Conference is set for November 14th, followed by the 35th Annual Piper Sandler Healthcare Conference on November 28th. The company focuses on reducing opioid usage by offering innovative non-opioid pain management solutions and has several approved treatments, including EXPAREL®, ZILRETTA®, and iovera®.
Price reaction · baseline $30.74 (2023-11-06 close) · hit after-hours · clean, no other PCRX news in the window
day 0 close · peak
-1.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Pacira BioSciences is participating in two major healthcare conferences, enhancing its visibility.
  • The company is committed to providing non-opioid pain management options, addressing a critical need in pain therapy.
  • Pacira has three commercial-stage non-opioid treatments available, indicating strong product development.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+19%
120-day peak, hindsight
Typical move
5.7%
average across 5 past catalysts
Lead asset
FX006
Phase 2 · Osteoarthritis of the Shoulder

Full Press Release Details

TAMPA, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:
Jefferies London Healthcare Conference on Tuesday, November 14th at 11:00AM GMT (6:00AM ET).
35th Annual Piper Sandler Healthcare Conference on Tuesday, November 28th at 2:00PM ET.
Live audio of the events can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcasts will also be available for two weeks following the events.
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

Frequently Asked Questions

What conferences will Pacira BioSciences attend?

Pacira will participate in the Jefferies London Healthcare Conference and the Piper Sandler Healthcare Conference.

When is the Jefferies London Healthcare Conference?

The Jefferies London Healthcare Conference is on November 14th at 11:00 AM GMT.

How can I access the live audio of the events?

Live audio can be accessed on Pacira's website under the 'Events' page.

What is Pacira's mission regarding opioids?

Pacira aims to provide non-opioid options and reduce opioid reliance in pain management.

What non-opioid treatments does Pacira offer?

Pacira offers EXPAREL®, ZILRETTA®, and ioveraº® for pain management.

Last updated: Nov 7, 2023